Start a TMS (Transcranial Magnetic Stimulation) Device Manufacturer

1. 1

   Accept that this is a funded, multi-year medtech venture

   Building a TMS device is not a side project. It requires several million dollars and up for R&D, FDA clearance, tooling, and commercialization, and 3 to 7 years before meaningful revenue. If you cannot assemble that capital and a team with medical-device and regulatory experience, the realistic entry point is operating a TMS clinic (a separate card) rather than manufacturing the equipment. Be honest with yourself and investors about the runway.

2. 2

   Define the clearance pathway early

   Neurostimulation devices in the United States generally reach market through the FDA 510(k) pathway by demonstrating substantial equivalence to a cleared predicate device, though novel designs can trigger a longer De Novo or PMA route. Your regulatory strategy shapes the entire budget and timeline, so bring in regulatory leadership before you finalize the design. A 510(k)/SaMD regulatory consultant (a separate card in this file) is a real line item here, not an afterthought.

3. 3

   Design the razor-and-blade model into the product

   The proven economics are not the box, they are the per-session stream. Capital equipment sells for 60,000 to 100,000 dollars per unit, but recurring per-treatment-session revenue historically exceeded 75 percent of total company revenue at scale. Design the device so each treatment session consumes an authenticated consumable or licensed treatment-link, so the recurring revenue is technically and contractually enforceable. This structural choice, made at design time, is what makes the business worth building.

4. 4

   Build the component and consumable supply chain

   The device depends on magnetic coil systems, precision electronics, and disposable per-session consumables from component manufacturers (a separate Tier 2 card in this file). Qualify suppliers who can meet medical-device quality standards and scale with you, and control the consumable so competitors cannot supply a cheaper blade for your razor. Supply-chain quality is also a regulatory obligation, not just an operations concern.

5. 5

   Sell to clinics and prove reimbursement

   Your buyers are psychiatric and neurology clinic operators who must invest 75,000 to 100,000 dollars up front before per-session revenue begins, so your sales motion has to prove the reimbursement math to them. Medicare reimburses roughly 160 to 180 dollars per treatment session against a typical six-week, 30-plus-session course, and your clinic customers need that coverage to justify the capital. Support them with reimbursement documentation, training, and clinical evidence, because their billing success is your recurring revenue.

6. 6

   Plan for reimbursement-driven margin compression

   This is the risk unique to clinical razor-and-blade models: as insurance coverage for TMS expands, payers push back on the per-session price, compressing the margin the manufacturer can charge on the blade. Consumer razor-and-blade businesses do not face a third party setting the blade price, but you will. Model your economics against tightening per-session reimbursement, diversify into new indications and channels, and do not build a plan that assumes today's per-session margin holds forever.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Experienced medtech founders and engineers with access to serious capital and a regulatory and reimbursement strategy, not first-time solo founders

Not for: This is not for a first-time or solo founder, a bootstrapper, or anyone without medical-device experience and serious capital. Those better fit the TMS clinic operator path (a separate card). It is a funded, multi-year, regulation-heavy venture with lower viability than the clinic side.